News | December 12, 2024
AbbVie completes acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Subscribe To Our Newsletter & Stay Updated
